Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.

Chromosome maintenance protein 1 (CRM1) is a nuclear export receptor involved in the active transport of tumor suppressors (e.g., p53 and nucleophosmin) whose function is altered in cancer because of increased expression and overactive transport. Blocking CRM1-mediated nuclear export of such proteins is a novel therapeutic strategy to restore tumor suppressor function. Orally bioavailable selective inhibitors of nuclear export (SINE) that irreversibly bind to CRM1 and block the function of this protein have been recently developed. Here we investigated the antileukemic activity of KPT-SINE (KPT-185 and KPT-276) in vitro and in vivo in acute myeloid leukemia (AML). KPT-185 displayed potent antiproliferative properties at submicromolar concentrations (IC50 values; 100-500 nM), induced apoptosis (average 5-fold increase), cell-cycle arrest, and myeloid differentiation in AML cell lines and patient blasts. A strong down-regulation of the oncogene FLT3 after KPT treatment in both FLT3-ITD and wild-type cell lines was observed. Finally, using the FLT3-ITD-positive MV4-11 xenograft murine model, we show that treatment of mice with oral KPT-276 (analog of KPT-185 for in vivo studies) significantly prolongs survival of leukemic mice (P < .01). In summary, KPT-SINE are highly potent in vitro and in vivo in AML. The preclinical results reported here support clinical trials of KPT-SINE in AML.

[1]  Lynda Chin,et al.  Preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC). , 2012 .

[2]  G. Marcucci,et al.  Abstract 3839: Nuclear export (karyopherin) inhibitors: A novel therapeutic strategy for treating Philadelphia-positive (Ph+) acute leukemias , 2012 .

[3]  D. Sullivan,et al.  Nuclear export of proteins and drug resistance in cancer. , 2012, Biochemical pharmacology.

[4]  A. Azmi,et al.  Novel small-molecule CRM-1 inhibitor for GI cancer therapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Byrd,et al.  CRM1/XPO1 Represents a Promising Therapeutic Target for Treatment of Chronic Lymphocytic Leukemia , 2011 .

[6]  Donald W Kufe,et al.  CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. , 2011, Blood.

[7]  G. Draetta,et al.  Cytotoxicity of novel, small molecule, CRM1-selective inhibitors of nuclear export (SINE) in colorectal cancer (CRC) cells. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Draetta,et al.  Preclinical Development of Small-Molecule CRM1 Inhibitors as Novel Therapy for the Treatment of Myeloma and Other Hematological Malignancies , 2010 .

[9]  J. Clohessy,et al.  The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. , 2010, Blood.

[10]  T. Stiewe,et al.  Oncogenic RAS Enables DNA Damage- and p53-Dependent Differentiation of Acute Myeloid Leukemia Cells in Response to Chemotherapy , 2009, PloS one.

[11]  B. Falini,et al.  Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives , 2009, Current opinion in oncology.

[12]  S. R. Hann,et al.  The Myc-Nucleophosmin-ARF network: A complex web unveiled , 2009, Cell cycle.

[13]  M. Alcalay,et al.  Role of nucleophosmin in acute myeloid leukemia , 2009, Expert review of anticancer therapy.

[14]  Chun Cheng,et al.  EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSIS , 2009, Neurosurgery.

[15]  S. Pileri,et al.  Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications , 2009, Leukemia.

[16]  M. Birrer,et al.  The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation , 2009, International journal of cancer.

[17]  S. Mutka,et al.  Identification of nuclear export inhibitors with potent anticancer activity in vivo. , 2009, Cancer research.

[18]  D. Sullivan,et al.  CRM1-mediated nuclear export of proteins and drug resistance in cancer. , 2008, Current medicinal chemistry.

[19]  Carsten Denkert,et al.  Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer , 2008, Cancer.

[20]  M. Gordon.  Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study , 2008 .

[21]  S. Hanai,et al.  Inhibition of Crm1–p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation , 2007, Nature Cell Biology.

[22]  R. Kehlenbach,et al.  CRM1-mediated nuclear export: to the pore and beyond. , 2007, Trends in cell biology.

[23]  Brunangelo Falini,et al.  Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.

[24]  C. Bloomfield,et al.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? , 2007, Blood.

[25]  Hartmut Döhner,et al.  Acute myeloid leukaemia , 2006, The Lancet.

[26]  C. Bloomfield,et al.  Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Pier Paolo Pandolfi,et al.  Nucleophosmin and cancer , 2006, Nature Reviews Cancer.

[28]  W. Hiddemann,et al.  Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. , 2006, Blood.

[29]  K. Fukasawa,et al.  Characterization of centrosomal association of nucleophosmin/B23 linked to Crm1 activity , 2005, FEBS letters.

[30]  N. Bolli,et al.  Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin , 2005, Leukemia.

[31]  X. Wang,et al.  Temporal and spatial control of nucleophosmin by the Ran–Crm1 complex in centrosome duplication , 2005, Nature Cell Biology.

[32]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[33]  R. Smart,et al.  C/EBPα Is a DNA Damage-Inducible p53-Regulated Mediator of the G1 Checkpoint in Keratinocytes , 2004, Molecular and Cellular Biology.

[34]  T. Cotter,et al.  Bcr‐Abl upregulates cytosolic p21WAF‐1/CIP‐1 by a phosphoinositide‐3‐kinase (PI3K)‐independent pathway , 2003, British journal of haematology.

[35]  B. Calabretta,et al.  Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation. , 2003, Blood.

[36]  G. Cingolani,et al.  Nucleocytoplasmic Transport: Navigating the Channel , 2003, Traffic.

[37]  Daniel G. Tenen,et al.  Disruption of differentiation in human cancer: AML shows the way , 2003, Nature Reviews Cancer.

[38]  L. Hengst,et al.  CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. , 2003, Molecular biology of the cell.

[39]  Martin Dugas,et al.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. , 2002 .

[40]  Pier Giuseppe Pelicci,et al.  Nucleophosmin regulates the stability and transcriptional activity of p53 , 2002, Nature Cell Biology.

[41]  Torsten Haferlach,et al.  AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia , 2001, Nature Medicine.

[42]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[43]  Karen H. Vousden,et al.  The ins and outs of p53 , 2000, Nature Cell Biology.

[44]  Ø. Bruserud,et al.  New Strategies for the Treatment of Acute Myelogenous Leukemia: Differentiation Induction—Present Use and Future Possibilities , 2000, Stem cells.

[45]  G. Wahl,et al.  A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking , 1999, The EMBO journal.

[46]  Kleanthis G. Xanthopoulos,et al.  Biological Role of the CCAAT/Enhancer-binding Protein Family of Transcription Factors* , 1998, The Journal of Biological Chemistry.

[47]  Minoru Yoshida,et al.  CRM1 is responsible for intracellular transport mediated by the nuclear export signal , 1997, Nature.

[48]  C. Dargemont,et al.  Evidence for a role of CRM1 in signal-mediated nuclear protein export. , 1997, Science.

[49]  J. Licht,et al.  Transcription factors, normal myeloid development, and leukemia. , 1997, Blood.

[50]  E. Newlands,et al.  Phase I trial of elactocin. , 1996, British Journal of Cancer.

[51]  H. Kitayama,et al.  Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. , 1991, Blood.